盐酸羟嗪(Hydroxyzine Hydrochloride) - 药物靶点：H1 receptor_在研适应症：荨麻疹，焦虑症，抑郁症_专利_临床

概要

基本信息

简介Hydroxyzine是一种一代抗组胺药，通常用于治疗各种过敏症状，如荨麻疹和瘙痒。它通过阻止组胺的作用来起到止痒的作用，组胺是一种在过敏反应中释放的化学物质，会引起瘙痒、肿胀和皮疹等症状。Hydroxyzine有口服和注射制剂，患者通常耐受性良好。然而，它可能会导致嗜睡、头晕和口干等副作用。作为研究和开发研究人员，需要注意的是，目前正在研究Hydroxyzine在治疗焦虑症方面的潜在用途，因为它在临床前研究中展示出一些抗焦虑的作用。

药物类型

小分子化药

别名

Hychotine、Hydroxine、Hydroxizine

+ [13]

靶点

H1 receptor

作用机制

H1 receptor拮抗剂(组胺H1受体拮抗剂)

治疗领域

免疫系统疾病神经系统疾病皮肤和肌肉骨骼疾病+ [1]

在研适应症

非在研适应症

原研机构

在研机构

非在研机构

最高研发阶段批准上市

首次获批日期

美国 (1956-04-12),

焦虑症瘙痒荨麻疹

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构

分子式C21H29Cl3N2O2

InChIKeyANOMHKZSQFYSBR-UHFFFAOYSA-N

CAS号2192-20-3

关联

26

项与盐酸羟嗪相关的临床试验

CTRI/2024/10/074754 / Not yet recruitingN/A

A Prospective Non-comparative Real-World Observational effectiveness and tolerability Study of Hydroxyzine Hydrochloride 50mg Sustain Release formulation for the management of Chronic Pruritus - Atarax SR

开始日期2024-10-31

申办/合作机构

Dr. Reddy's Laboratories Ltd.

NCT05737511 / Not yet recruiting临床4期IIT

Efficacy of Hydroxyzine Versus Treatment as Usual for Panic Disorder: An Eight-Week, Open Label, Pilot, Randomized Controlled Trial.

The aim of this study is to evaluate the efficacy of hydroxyzine compared to treatment as usual (TAU) for patients with panic disorder. By conducting a pilot study, we hope to provide initial data on the feasibility and potential impact of hydroxyzine for this population. This will inform the design and power calculations of a larger, more comprehensive study in the future.
Objectives:
To assess the feasibility of conducting a randomized controlled trial (RCT) of hydroxyzine for panic disorder.
To evaluate the effectiveness of hydroxyzine compared to TAU in reducing panic symptoms in patients with panic disorder.
To explore the potential side effects and tolerability of hydroxyzine in this population.
Methods:
This will be a single-center, open-label, randomized pilot study. A total of 30 patients with a primary diagnosis of panic disorder will be recruited from a psychiatric outpatient clinic. Participants will be randomly assigned to receive either hydroxyzine or TAU for 8 weeks. The primary outcome measure will be the change in panic symptoms as assessed by the Panic Disorder Severity Scale (PDSS). Secondary outcome measures will include the Hamilton Anxiety Rating Scale (HAM-A) and the Clinical Global Impression-Severity (CGI-S) scale. Participants will be assessed at baseline, 4 weeks, and 8 weeks. Adverse events will be monitored throughout the study.
Expected Results:
This pilot study is expected to provide preliminary data on the feasibility and potential efficacy of hydroxyzine for panic disorder. The results will inform the design of a larger RCT to further evaluate the efficacy of hydroxyzine for this population.
Significance:
There is a need for effective and well-tolerated treatments for panic disorder. If found to be effective, hydroxyzine could provide a new option for patients with this condition, potentially improving their quality of life and functioning. The results of this pilot study will inform the design of future studies and contribute to the development of evidence-based treatments for panic disorder.

开始日期2023-12-30

申办/合作机构

University of Sultan Qaboos

NCT05680584 / Recruiting临床1期IIT

Comparison Between the Effect of Oral Melatonin and Hydroxyzine for Preventing Preoperative Anxiety in Pediatric Patients Undergoing Adenotonsillectomy

Comparison between the effect of oral Melatonin and Hydroxyzine for Preventing Preoperative Anxiety in pediatric Patients Undergoing Adenotonsillectomy

开始日期2023-02-01

申办/合作机构-

100 项与盐酸羟嗪相关的临床结果

登录后查看更多信息

100 项与盐酸羟嗪相关的转化医学

登录后查看更多信息

100 项与盐酸羟嗪相关的专利（医药）

登录后查看更多信息

1,402

项与盐酸羟嗪相关的文献（医药）

2024-12-31·ANNALS OF MEDICINE

Psychotherapeutic and pharmacological agents for post-traumatic stress disorder with sleep disorder: network meta-analysis

Review

作者: Luo, Jie ; Zhang, Zhi-Xin ; Liu, Jia-Ling ; Huang, Cheng-Yang ; Yue, Li ; Zhang, Chao ; Liu, Run-Ben ; Zhao, Yi-Fan ; Li, Xiao-Zheng

OBJECTIVE:

The current guidelines and canonical norms of diagnosis or treatment for Post-traumatic stress disorder (PTSD) with sleep disorder are still conflicting and have not yet reached a consensus. This study aimed to unravel the most effective countermeasures between two categories (psychotherapy and pharmacotherapy) put forward by the National Institute for Health and Clinical Excellence (NICE) and World Federation of Societies of Biological Psychiatry (WFSBP) respectively to treat PTSD individuals co-exist with sleep disorders.

METHODS:

Four databases, including PubMed, EMBASE, Cochrane Library, and APA PsyNet, were searched from inception to February 02, 2023.

RESULTS:

Twenty articles with 24 Randomized controlled trials (RCTs) and a total number of 1,647 participants were included. As demonstrated in the network meta-analysis comparison results, CBT-I (standardized mean differences (SMD) = -1.51,95% confidence interval (CI):-2.55 to -0.47), CBT-I plus IRT (SMD = -1.71, 95%CI:-3.39, -0.03), prazosin (SMD = -0.87,95%CI:-1.59 to -0.16) and hydroxyzine (SMD = -1.06, 95%CI: -1.94 to -0.19) significantly reduced PTSD symptoms compared with placebo. In contrast to placebo, CBT-I (SMD = -5.61,95%CI:-8.82 to -2.40) significantly improved sleep quality. For nightmare severity, IRT (SMD =-0.65, 95%CI:-1.00 to -0.31), prazosin (SMD = -1.20,95%CI:-1.72 to -0.67) and hydroxyzine (SMD = -0.98,95%CI:-1.58 to -0.37) significantly reduced nightmare severity in comparison with placebo.

CONCLUSIONS:

This study suggested that under most circumstances, psychotherapy namely CBT-I had a favorable profile, but pharmacotherapy with prazosin was effective in managing nightmare severity. The sole avail of CBT-I was recommended to improving sleep quality while CBT-I and CBT-I plus IRT showed excellent management of PTSD symptom severity. Exposure to CBT-I isrecommended for depression. The relevant clinical guidelines for the management of individuals with PTSD and sleep disorders may regard this as a reference.

PROSPERO:

CRD42023415240.

2024-12-01·JOURNAL OF PALLIATIVE MEDICINE

Managing Pruritus in Advanced Chronic Disease

Review

作者: McDonald, Gord ; Kaya, Ebru ; Gallagher, Romayne

Even though pruritus affects a significant number of people with chronic disease, it is rarely adequately treated. Drug therapies often rely on antihistamines, which have not shown to be beneficial in systemic pruritus. Hydroxyzine is frequently used to treat pruritus associated with kidney failure. Since Canada's sole manufacturer of hydroxyzine is no longer making this product, this is an ideal time to review the mechanisms of itch in advanced organ failure and the specific therapies that give relief. Although there is literature describing itch in patients with cancer, this article is limited to pathogenesis and treatment of systemic itch secondary to chronic, noncancer diseases. We summarize recent systematic reviews, although the studies included in these reviews are often small, and mostly cohort studies.

2024-12-01·RADIOTHERAPY AND ONCOLOGY

Effects of dopamine receptor antagonists and radiation on mouse neural stem/progenitor cells

Article

作者: Pajonk, Frank ; Ioannidis, Angeliki ; He, Ling ; Bhat, Kruttika

BACKGROUND:

Dopamine receptor antagonists have recently been identified as potential anti-cancer agents in combination with radiation, and a first drug of this class is in clinical trials against pediatric glioma. Radiotherapy causes cognitive impairment primarily by eliminating neural stem/progenitor cells and subsequent loss of neurogenesis, along with inducing inflammation, vascular damage, and synaptic alterations. Here, we tested the combined effects of dopamine receptor antagonists and radiation on neural stem/progenitor cells.

METHODS:

Using transgenic mice that report the presence of neural stem/progenitor cells through Nestin promoter-driven expression of EGFP, the effects of dopamine receptor antagonists alone or in combination with radiation on neural stem/progenitor cells were assessed in sphere-formation assays, extreme limiting dilution assays, flow cytometry and real-time PCR in vitro and in vivo in both sexes.

RESULTS:

We report that hydroxyzine and trifluoperazine exhibited sex-dependent effects on murine newborn neural stem/progenitor cells in vitro. In contrast, amisulpride, nemonapride, and quetiapine, when combined with radiation, significantly increased the number of neural stem/progenitor cells in both sexes. In vivo, trifluoperazine showed sex-dependent effects on adult neural stem/progenitor cells, while amisulpride demonstrated significant effects in both sexes. Further, amisulpride increased sphere forming capacity and stem cell frequency in both sexes when compared to controls.

CONCLUSION:

We conclude that a therapeutic window for dopamine receptor antagonists in combination with radiation potentially exists, making it a novel combination therapy against glioblastoma. Normal tissue toxicity following this treatment scheme likely differs depending on age and sex and should be taken into consideration when designing clinical trials.

1

项与盐酸羟嗪相关的新闻（医药）

2023-06-02

·赛柏蓝

百亿大品种，独家重磅首仿：右酮洛芬氨丁三醇注射液获批上市

据NMPA官网信息显示，南京正科医药股份有限公司的右酮洛芬氨丁三醇注射液已于5月29日获批生产并视同过评。右酮洛芬氨丁三醇注射液是新一代安全强效的非甾体类抗炎镇痛药（NSAIDs），用于围术期术后中度至重度疼痛，NSAIDs2022年在中国公立医疗机构终端的销售额超过100亿。 01围术期镇痛用药是一个巨大的、极具前景的市场术后疼痛是临床最常见且最需紧急处理的并发症，持续性术后疼痛主要表现为社会心理问题、术后疼痛控制不佳、神经损伤等，如果处理不当，术后疼痛会持续2个月，然后转为慢性疼痛。国内一份2013年的研究证实，73.8%的术后患者会经历中度到重度疼痛，而另一项2021年针对630名患者的问卷调查显示达75%以上患者经历了术后疼痛。临床开展术后镇痛20余年，提出和开展了包括患者自控镇痛（PCA）、多模式镇痛、预防性镇痛的新技术和新方法，逐渐形成了体系完善的镇痛药物临床使用方案。02非甾体类抗炎药（NSAIDs）是PCA及多模式镇痛的基础用药根据PDB销售数据，NSAIDs2019年样本医院销售额约26.77亿元，测算城市公立医院销售规模超100亿元，2020年销售额下降主要受疫情与集采落地的影响；从销售数量看，NSAIDs近5年呈稳步增长趋势。2022年PDB的NSAIDsTOP10品种依次为酮咯酸氨丁三醇、氟比洛芬、艾瑞昔布、布洛芬、塞来昔布、帕瑞昔布、双氯芬酸、依托考昔、右布洛芬、吲哚美辛，销售额占总体的87.59%，销售数量约占68.33%。NSAIDs市场竞争激烈，11款大品种尽收国家带量采购。其中用于术后镇痛的NSAIDs注射剂大品种已尽数纳入：氟比洛芬酯注射液、布洛芬注射液、注射用帕瑞昔布钠、酮咯酸氨丁三醇注射液。集采批次药物4+7及扩围氟比洛芬酯注射液第二轮美洛昔康片第三批布洛芬缓释胶囊，布洛芬颗粒依托考昔片塞来昔布胶囊第四批布洛芬片，布洛芬注射液洛索洛芬钠片注射用帕瑞昔布钠第八批酮咯酸氨丁三醇注射液03国内首仿，围术期镇痛用药，迎来重磅新品南京正科医药股份有限公司拿下右酮洛芬氨丁三醇注射液的首访，预计未来可保持多年国内独家，该品种是新一代安全强效的非甾体类抗炎镇痛药（NSAIDs），用于围术期术后中度至重度疼痛。右酮洛芬氨丁三醇注射液原研美纳里尼，最早于2002年获HMA批准上市, 尚未进入国内。因该药在术后疼痛、急性腰痛及肾绞痛等方面的有效持久的镇痛效果与良好的安全性，在欧洲各成员国获得广泛的临床应用。这款重磅新品在国内首访上市，引起了临床医生、药学专家的广泛关注。非甾体类抗炎药提纯旋光单成分是业界研发热门新方向，临床市售90%以上的NSAIDs均为消旋体。酮洛芬是手性药物，左旋酮洛芬临床表现为体外无活性且是引起不良反应的主要成分；右酮洛芬剔除了弱效、无效且副作用较大的左旋成分，保留了主要起效果的右旋成分，不仅有着双倍的镇痛强度，同时也减少了肝脏、肾脏的负荷和代谢产物，在临床上表现出COX-1和COX-2两个通路上的均衡抑制，在临床使用中表现出更少的胃肠道不良反应。右酮洛芬氨丁三醇注射液具有较好的相容性，在小体积容器中（如注射器中）与肝素、利多卡因、吗啡和茶碱注射溶液混合，经100ml生理盐水或葡萄糖溶液稀释后，可与多巴胺、肝素、羟嗪、利多卡因、吗啡、哌替啶和茶碱相容。国内临床也支持右酮洛芬氨丁三醇注射液入泵使用，在临床使用上有较好的便捷性。右酮洛芬氨丁三醇注射液快速持久，10~45分钟即达镇痛峰值，长效作用8~12h，满足镇痛临床需求，稳定减少联合使用时阿片类药物的用量。临床推荐剂量为每8~12小时50mg，必要时可于6小时后重复给药。据NMPA官网信息显示，南京正科医药股份有限公司的右酮洛芬氨丁三醇注射液已于5月29日正式获得生产批件。作为新一代安全强效的非甾体类抗炎镇痛药（NSAIDs），其强效持久的镇痛效果、良好的安全性及临床使用的便捷性，定能为临床使用及患者带来福音。南京正科医药股份有限公司全国招商热线020-3803328813902285184（微信同号）13829751846（微信同号）

带量采购上市批准核酸药物

100 项与盐酸羟嗪相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00672	盐酸羟嗪	N05BB01	DB00557

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
抑郁症	日本	Pfizer Inc.	1965-09-30
湿疹	日本	Pfizer Inc.	1965-09-30
恶心和呕吐	日本	Pfizer Inc.	1965-09-30
焦虑症	美国	Pfizer Inc.	1956-04-12
瘙痒	美国	Pfizer Inc.	1956-04-12
荨麻疹	美国	Pfizer Inc.	1956-04-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05126459 (CTgov)	临床3期	龋齿	60	Meperidine+Hydroxyzine +Midazolam (Regimen 1)	簾觸壓蓋願醖餘鏇範構(淵襯顧範鹹顧網鹽積糧) = 夢顧構餘憲憲壓醖襯襯壓繭衊鑰網醖襯齋觸積 (願築糧鹽繭構築廠淵構, 醖蓋積窪簾鬱範鏇願鑰 ~ 遞鏇夢構醖蓋艱願窪鹹) 更多	-	2024-10-02
NCT05126459 (CTgov)	临床3期	龋齿	60	Meperidine+Hydroxyzine (Regimen 2)	簾觸壓蓋願醖餘鏇範構(淵襯顧範鹹顧網鹽積糧) = 觸廠壓簾襯壓鏇壓繭製壓繭衊鑰網醖襯齋觸積 (願築糧鹽繭構築廠淵構, 膚夢範醖憲繭築鑰糧獵 ~ 窪憲積繭餘廠襯獵窪齋) 更多	-	2024-10-02
NCT04068948 (CTgov)	临床4期	镇静 \| 龋齿	37	Meperidine+Hydroxyzine+Midazolam (Midazolam, Hydroxyzine, Meperidine)	齋鹽壓鏇築夢憲鹹鑰醖(夢鹹膚選淵簾繭製膚鹹) = 繭鏇醖觸鹹願獵鬱遞構繭淵糧襯繭壓觸鏇鏇製 (醖夢鏇衊艱糧築襯醖鹹, 衊齋遞膚顧壓廠繭遞膚 ~ 夢繭鹽夢築顧糧鏇糧衊) 更多	-	2023-12-05
NCT04068948 (CTgov)	临床4期	镇静 \| 龋齿	37	Hydroxyzine+Midazolam (Midazolam, Hydroxyzine)	齋鹽壓鏇築夢憲鹹鑰醖(夢鹹膚選淵簾繭製膚鹹) = 鹹壓獵鬱糧遞餘窪膚構繭淵糧襯繭壓觸鏇鏇製 (醖夢鏇衊艱糧築襯醖鹹, 窪醖觸鹹憲夢醖簾醖觸 ~ 製觸艱積鏇憲簾襯餘膚) 更多	-	2023-12-05
NCT04188106 (HAVE, CTgov)	临床4期	恶心 \| 睡眠异常 \| 尼古丁成瘾	26	Varenicline Pill+Hydroxyzine Pill	蓋選餘觸膚網鏇鹹糧壓(獵糧夢遞繭蓋壓壓積鏇) = 鹽壓襯獵鹹選遞醖獵窪蓋齋鏇衊憲衊鏇鏇網夢 (餘繭選艱鹹鑰鑰艱網廠, 顧鹹顧獵壓觸製糧鏇窪 ~ 積鏇獵願齋齋選製鏇醖) 更多	-	2023-03-03
ASCO2005	N/A	骨痛	-	G-CSF administration	蓋積鹽遞襯製鹽齋顧蓋(範積選鹹構製襯憲鏇構) = The bone pain frequently emerges as one of the side effects of G-CSF administration. Rising pressure within bone marrow by increased granulocytes, edema within bone marrow by histamine release, and increased level of bradykinin are thought to be the mechanisms underlying it. The incidence of bone pain is reported to be 1–5% of all cases, but in practice we have the impression that there have been more cases with bone pain, some of which are resistant to treatment with non-steroid anti-inflammatory drugs (NSAIDs). 衊衊顧製鑰艱鏇鏇構蓋 (廠壓窪願選憲壓窪夢壓 )	-	2005-06-01